Kineta and Genentech extended research collaboration to develop a first-in-class α9/α10 nAchR antagonist for the treatment of chronic pain

Kineta Chronic Pain, a subsidiary of Kineta, announced that the company will extend and expand its research collaboration with Genentech to advance a first-in-class α9/α10 nAchR antagonist, KCP506, for the treatment of chronic pain into Phase 1 clinical trials. Kineta will also receive an undisclosed payment from Genentech to extend the research collaboration.

Kineta initially established a research collaboration and option agreement with Genentech in April 2018. Under the terms of the agreement, Genentech has an option to license assets developed during the research collaboration.

KCP506 is a first-in-class α9α10 nAChR antagonist in development for the treatment of chronic neuropathic pain. Kineta recently received Clinical Trial Application approval from the Netherlands to initiate Phase 1 trials of KCP506. A single ascending dose and multiple ascending dose study will be conducted in healthy subjects to evaluate the safety, tolerability, and pharmacokinetics of KCP506 and will commence in Q4 2020.

Read the press release here.

Read more about Kineta here.

Read more about Genentech here.

Photo by Thirdman from Pexels